-
1
-
2Academic Journal
Authors: Гуламов О.М., Тошкенбоев Ф.Р., Ахмедов Ғ.К., Тоиров А.С., Амеров Д.А.
Subject Terms: Калит сўзлар: меъда яра касаллиги, аденокарцинома, лапароскопик гастрэктомия
Relation: https://zenodo.org/communities/rf2181-3833/; https://zenodo.org/records/14833772; oai:zenodo.org:14833772; https://doi.org/10.5281/zenodo.14833772
-
3Academic Journal
Authors: Курбанович, Нарзиев Йулдош
Source: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 4 No. 1 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 204-206 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 4 № 1 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 204-206 ; 2181-3469
Subject Terms: рак желудка, лапароскопическая гастрэктомия, эндовидеохирургия, лимфодиссекция, онкологическая радикальность
File Description: application/pdf
-
4Academic Journal
-
5Academic Journal
-
6Academic Journal
Authors: E. A. Toneev, E. A. Keshyan, D. I. Nuretdinov, A. A. Martynov, A. V. Zhinov, R. F. Shagdaleev, Е. А. Тонеев, Э. А. Кешян, Д. И. Нуретдинов, А. А. Мартынов, А. В. Жинов, Р. Ф. Шагдалеев
Source: Siberian journal of oncology; Том 23, № 4 (2024); 108-116 ; Сибирский онкологический журнал; Том 23, № 4 (2024); 108-116 ; 2312-3168 ; 1814-4861
Subject Terms: панкреатическая фистула, gastrectomy, pancreatic fistula, гастрэктомия
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/3197/1256; Состояние онкологической помощи населению России в 2020 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021. 239 с.; Sexton R.E., Al Hallak M.N., Diab M., Azmi A.S. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020; 39(4): 1179–203. doi:10.1007/s10555-020-09925-3.; Katai H., Ishikawa T., Akazawa K., Isobe Y., Miyashiro I., Oda I., Tsujitani S., Ono H., Tanabe S., Fukagawa T., Nunobe S., Kakeji Y., Nashimoto A.; Registration Committee of the Japanese Gastric Cancer Association. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018; 21(1): 144–54. doi:10.1007/s10120-017-0716-7.; Bassi C., Marchegiani G., Dervenis C., Sarr M., Abu Hilal M., Adham M., Allen P., Andersson R., Asbun H.J., Besselink M.G., Conlon K., Del Chiaro M., Falconi M., Fernandez-Cruz L., Fernandez-Del Castillo C., Fingerhut A., Friess H., Gouma D.J., Hackert T., Izbicki J., Lillemoe K.D., Neoptolemos J.P., Olah A., Schulick R., Shrikhande S.V., Takada T., Takaori K., Traverso W., Vollmer C.M., Wolfgang C.L., Yeo C.J., Salvia R., Buchler M.; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161(3): 584–91. doi:10.1016/j.surg.2016.11.014. Erratum in: Surgery. 2024. doi:10.1016/j.surg.2024.05.043.; Sano T., Sasako M., Mizusawa J., Yamamoto S., Katai H., Yoshikawa T., Nashimoto A., Ito S., Kaji M., Imamura H., Fukushima N., Fujitani K.; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017; 265(2): 277–83. doi:10.1097/SLA.0000000000001814.; Martiniuc A., Dumitrascu T., Ionescu M., Tudor S., Lacatus M., Herlea V., Vasilescu C. Pancreatic Fistula after D1+/D2 Radical Gastrectomy according to the Updated International Study Group of Pancreatic Surgery Criteria: Risk Factors and Clinical Consequences. Experience of Surgeons with High Caseloads in a Single Surgical Center in Eastern Europe. J Gastric Cancer. 2021; 21(1): 16–29. doi:10.5230/jgc.2021.21.e3.; Al-Magedi A.A.S., Wu R., Tao Q. Comparison of postoperative pancreatic fistula between open and laparoscopic surgery in patients with gastric cancer: A meta-analysis. Ann Med Surg (Lond). 2022; 76. doi:10.1016/j.amsu.2022.103558.; Kobayashi D., Iwata N., Tanaka C., Kanda M., Yamada S., Nakayama G., Fujii T., Koike M., Fujiwara M., Kodera Y. Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. J Surg Oncol. 2015; 112(4): 381–6. doi:10.1002/jso.24001.; Yu H.W., Jung D.H., Son S.Y., Lee C.M., Lee J.H., Ahn S.H., Park D.J., Kim H.H. Risk factors of postoperative pancreatic fistula in curative gastric cancer surgery. J Gastric Cancer. 2013; 13(3): 179–84. doi:10.5230/jgc.2013.13.3.179.; Sato Y., Inokuchi M., Otsuki S., Fujimori Y., Kojima K. Risk Factor of Pancreatic Fistula after Radical Gastrectomy from the Viewpoint of Fatty Pancreas. Dig Surg. 2017; 34(6): 455–61. doi:10.1159/000455332.; Tsujinaka T., Sasako M., Yamamoto S., Sano T., Kurokawa Y., Nashimoto A., Kurita A., Katai H., Shimizu T., Furukawa H., Inoue S., Hiratsuka M., Kinoshita T., Arai K., Yamamura Y.; Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol. 2007; 14(2): 355–61. doi:10.1245/s10434-006-9209-3.; Kumagai K., Hiki N., Nunobe S., Kamiya S., Tsujiura M., Ida S., Ohashi M., Yamaguchi T., Sano T. Impact of anatomical position of the pancreas on postoperative complications and drain amylase concentrations after laparoscopic distal gastrectomy for gastric cancer. Surg Endosc. 2018; 32(9): 3846–54. doi:10.1007/s00464-018-6114-3.; Kamiya S., Hiki N., Kumagai K., Honda M., Nunobe S., Ohashi M., Sano T., Yamaguchi T. Two-point measurement of amylase in drainage fluid predicts severe postoperative pancreatic fistula after gastric cancer surgery. Gastric Cancer. 2018; 21(5): 871–8. doi:10.1007/s10120-018-0805-2.; Yamada S., Yagi S., Sato K., Shin’e M., Sakamoto A., Utsunomiya D., Okikawa S., Aibara N., Watanabe M., Obatake M., Ono R., Fujii M., Otani H., Kawasaki H. Serum C-reactive protein level on first postoperative day can predict occurrence of postoperative pancreatic fistula after laparoscopic gastrectomy. J Med Invest. 2019; 66(3.4): 285–8. doi:10.2152/jmi.66.285.; Tanioka T., Kojima K., Saito T., Kanemoto E., Okuno K., Gokita K., Kobayashi K., Nakagawa M., Inokuchi M. Intraoperative Body Fluid Amylase as a Novel Indicator of Postgastrectomy Pancreatic Fistula. World J Surg. 2019; 43(8): 2061–8. doi:10.1007/s00268-019-04961-9.; Miyai H., Hara M., Hayakawa T., Takeyama H. Establishment of a simple predictive scoring system for pancreatic fistula after laparoscopyassisted gastrectomy. Dig Endosc. 2013; 25(6): 585–92. doi:10.1111/den.12042.; Garnier J., Alfano M.S., Robin F., Ewald J., Al Farai A., Palen A., Sebai A., Mokart D., Delpero J.R., Sulpice L., Zemmour C., Turrini O. Establishment and external validation of neutrophil-to-lymphocyte ratio in excluding postoperative pancreatic fistula after pancreatoduodenectomy. BJS Open. 2023; 7(1). doi:10.1093/bjsopen/zrac124.; https://www.siboncoj.ru/jour/article/view/3197
-
7Academic Journal
Authors: A. Yu. Anokhin, P. V. Kononets, D. Yu. Kanner, D. L. Stroyakovsky, A. O. Shveykin, A. E. Kalinin, V. Yu. Kirsanov, A. S. Tyulandina, А. Ю. Анохин, П. В. Кононец, Д. Ю. Каннер, Д. Л. Строяковский, А. О. Швейкин, А. Е. Калинин, В. Ю. Кирсанов, А. С. Тюляндина
Source: Surgery and Oncology; Том 14, № 1 (2024); 62-71 ; Хирургия и онкология; Том 14, № 1 (2024); 62-71 ; 2949-5857
Subject Terms: гастрэктомия, gastroesophageal junction cancer, locally advanced gastric cancer, perioperative chemotherapy, total neoadjuvant chemotherapy, pathomorphological regression, gastrectomy, рак кардиоэзофагеального перехода, местно-распространенный рак желудка, периоперационная химиотерапия, полная неоадъювантная химиотерапия, патоморфологический регресс опухоли
File Description: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/692/457; Давыдов М.И., Туркин И.Н., Давыдов М.М. Энциклопедия хирургии рака желудка. М.: Эксмо, 2011.; Шаназаров Н.А., Синяков А.Г., Райков Н.С. и др. Различные объемы лимфодиссекции в хирургическом лечении рака желудка. Тюменский медицинский журнал 2010;2:89–92.; Дмитриев Е.Г., Михайлова Н.В. Хирургическое лечение рака желудка: современное состояние и перспективы. Поволжский онкологический вестник 2010;4:74–81.; Catalano V., Labianca R., Beretta G. et al. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127–64. DOI:10.1016/j.critrevonc.2009.01.004; Бесова Н.С., Калинин А.Е., Неред С.Н. и др. Ассоциация онкологов России. Клинические рекомендации по лечению рака желудка. 2020 год. https://oncology-association.ru/wp-content/uploads/2020/09/rak_zheludka.pdf; Cunningham D., Allum W., Stenning S. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20. DOI:10.1056/NEJMoa055531; Al-Batran S.E., Homann N., Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–57. DOI:10.1016/S0140-6736(18)32557-1; Бесова Н.С., Болотина Л.В., Гамаюнов С.В. и др. Практические рекомендации по лекарственному лечению рака желудка. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли 2023;13(3):405–24. DOI:10.18027/2224-5057-2023-13-3s2-1-405-424; NCCN Clinical Practice Guidelines in oncology. Gastric cancer. – National Comprehensive Cancer Network, version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf; Ychou M., Boige V., Pignon J. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. JCO 2011;29(13):1715–21. DOI:10.1200/JCO.2010.33.0597; Mandard A., Dalibard F., Mandard J. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73(11):2680–6. DOI:10.1002/1097-0142(19940601)73:113.0.co;2-c; Ma J., Jianhui L., Meirui Q. et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N). Diagn Pathol 2018;13(1):91–101. DOI:10.1186/s13000-018-0766-0; Giommoni E., Lavacchi D., Tirino G. et al. Results of the observational prospective RealFLOT study. BMC Cancer 2021;21:1086–96. DOI:10.1186/s12885-021-08768-7; Muro K., Chung H.C., Shankaran V. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717–26. DOI:10.1016/S1470-2045(16)00175-3; Smyth E., Wotherspoon A., Peckitt C. et al. Mismatch repair deficiency, microsatellite instability, and survival an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol 2017;3(9):1197–203. DOI:10.1001/jamaoncol.2016.6762; Сунь Х., Неред С.Н., Трякин А.А. и др. Результаты комбинированного лечения резектабельного рака желудка в зависимости от статуса микросателлитной нестабильности. Тазовая хирургия и онкология 2023;13(2):17–26. DOI:10.17650/2686-9594-2023-13-2-17-26
-
8Academic Journal
Source: Евразийский онкологический журнал. :159-168
Subject Terms: 03 medical and health sciences, роботическая гастрэктомия, 0302 clinical medicine, gastric cancer, laparoscopic gastrectomy, robotic gastrectomy, рак желудка, лапароскопическая гастрэктомия, 3. Good health
-
9Academic Journal
Source: PAEDIATRIC SURGERY. UKRAINE; No. 2(79) (2023): Paediatric surgery (Ukraine); 105-110
ХИРУРГИЯ ДЕТСКОГО ВОЗРАСТА; № 2(79) (2023): Paediatric surgery (Ukraine); 105-110
Хірургія дитячого віку; № 2(79) (2023): Хірургія дитячого віку (Україна); 105-110Subject Terms: кровотечение, stomach cancer, esophagoduodenoanastomosis, езофагодуоденоанастомоз, гастректомія, гастрэктомия, эзофагодуоденоанастомоз, рак шлунка, bleeding, рак желудка, кровотеча, gastrectomy, 3. Good health
File Description: application/pdf
Access URL: http://psu.med-expert.com.ua/article/view/285834
-
10Academic Journal
Authors: Chandra Hassan, Stephan Gruessner, Pier Cristoforo Giulianotti, Francesco Bianco, Valentina Valle, Yevhen Pavelko, Antonio Gangemi
Source: Clinical Endocrinology and Endocrine Surgery. Клінічна ендокринологія та ендокринна хірургія; № 4 (2020); 8-13
Clinical Endocrinology and Endocrine Surgery; No. 4 (2020); 8-13
Clinical Endocrinology and Endocrine Surgery. Клиническая эндокринология и эндокринная хирургия; № 4 (2020); 8-13Subject Terms: 2. Zero hunger, повністю роботизована рукавна гастректомія, аспиранты, 9. Industry and infrastructure, fellows, аспіранти, totally robotic sleeve gastrectomy, співробітники, сотрудники, 3. Good health, навчальна модель, полностью роботизированная рукавная гастрэктомия, training model, 616.33-089.87-089.819, учебная модель, residents
File Description: application/pdf
-
11Academic Journal
Authors: V. Yu. Skoropad, D. Yu. Mironova, I. V. Kolobaev, T. A. Agababyan, E. S. Zhavoronkova, V. N. Grinevich, S. A. Ivanov, A. D. Kaprin, В. Ю. Скоропад, Д. Ю. Миронова, И. В. Колобаев, Т. А. Агабабян, Е. С. Жаворонкова, В. И. Гриневич, С. А. Иванов, А. Д. Каприн
Source: Siberian journal of oncology; Том 22, № 3 (2023); 153-161 ; Сибирский онкологический журнал; Том 22, № 3 (2023); 153-161 ; 2312-3168 ; 1814-4861
Subject Terms: безрецидивная выживаемость, neoadjuvant chemoradiotherapy, pathological response, gastrectomy, disease-free survival, неоадъювантная химиолучевая терапия, лечебный патоморфоз, гастрэктомия
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2588/1115; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-49. doi:10.3322/caac.21660.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2022. 252 с.; Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., Lindig U., Schmiegel W., Pohl M., Stoehlmacher J., Folprecht G., Probst S., Prasnikar N., Fischbach W., Mahlberg R., Trojan J., Koenigsmann M., Martens U.M., Thuss-Patience P., Egger M., Block A., Heinemann V., Illerhaus G., Moehler M., Schenk M., Kullmann F., Behringer D.M., Heike M., Pink D., Teschendorf C., Lohr C., BernhardH., Schuch G., Rethwisch V, von Weiker-sthal L.F., Hartmann J.T., Kneba M., Daum S., Schulmann K., Weniger J., Belle S., Gaiser T., Oduncu F.S., Guntner M., Hozaeel W., Reichart A., JagerE., Kraus T., MonigS., Bechstein W.O., SchulerM., SchmalenbergH., Hofheinz R.D.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 1948-57. doi:10.1016/S0140-6736(18)32557-1.; Leong T., Smithers B.M., Haustermans K., Michael M., Gebski V., Miller D., Zalcberg J., Boussioutas A., Findlay M., O'Connell R.L., Verghis J., Willis D., Kron T., Crain M., Murray W.K., Lordick F., Swallow C., Darling G., Simes J., Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017; 24(8): 2252-8. doi:10.1245/s10434-017-5830-6.; Liu X., Jin J., Cai H., Huang H., Zhao G., Zhou Y., Wu J., Du C., Long Z., Fang Y., Ma M., Li G., Zhou M., Yin J., Zhu X., Zhu J., Sheng W., Huang D., Zhu H., Zhang Z., Lu Q., Xie L., Zhang Z., Wang Y. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer. 2019; 19(1): 606. doi:10.1186/s12885-019-5728-8.; Slagter A.E., JansenE.PM., van LaarhovenH.W.M., van Sandick J.W., van Grieken N.C.T., Sikorska K., Cats A., Muller-Timmermans P., Hul-shofM.C.CM., BootH., LosM., BeerepootL.V, PetersF.P.J., HospersGA.P., van Etten B., HartgrinkH.H., van Berge HenegouwenM.I., Nieuwenhui-jzen G.A.P., van Hillegersberg R., van der Peet D.L., Grabsch H.I., Verheij M. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018; 18(1): 877. doi:10.1186/s12885-018-4770-2.; Su P., Zhang Y., Yu T., Jiang L., Kang W., Liu Y., Yu J. Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer? World J Surg Oncol. 2022; 20(1): 408. doi:10.1186/s12957-022-02881-y.; Petrelli F., Tomasello G., Barni S. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. Eur J Cancer. 2017; 76: 8-16. doi:10.1016/j.ejca.2017.01.032.; Tomasello G., Petrelli F., Ghidini M., Pezzica E., Passalacqua R., Steccanella F., Turati L., Sgroi G., Barni S. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A metaanalysis of 17 published studies. Eur J Surg Oncol. 2017; 43(9): 1607-16. doi:10.1016/j.ejso.2017.03.001.; Stark A.P., IkomaN., Chiang Y.J., Estrella J.S., Das P, MinskyB.D., Blum M.M., Ajani J.A., Mansfield P., Badgwell B.D. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019; 26(11): 3602-10. doi:10.1245/s10434-019-07638-8.; Скоропад В.Ю., Кудрявцев Д.Д., Титова Л.Н., Мозеров С.А., Агабабян Т.А., Иванов С.А., Каприн А.Д. Лечебный патоморфоз после неоадъювантной химиолучевой терапии у больных местнораспространенным раком желудка. Сибирский онкологический журнал. 2020; 19(3): 38-46. doi:10.21294/1814-4861-2020-19-3-38-46.; Pelc Z., Skorzewska M., Rawicz-Pruszynski K., Polkowski W.P. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective. Cancers (Basel). 2021; 13(10): 2509. doi:10.3390/cancers13102509.; Wu L., Xing Z., Huang M., Yu H., Qin Y., Jin Q., Zhou Z., Chen J. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients. J Surg Oncol. 2022; 126(8): 1403-12. doi:10.1002/jso.27065.; Ikoma N., Estrella J.S., Hofstetter W., Das P., Minsky B.D., Ajani J.A., Fournier K.F., Mansfield P., Badgwell B.D. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018; 25(7): 2012-17. doi:10.1245/s10434-018-6471-0.; Ikoma N., Hofstetter W.L., Estrella J.S., Das P., Minsky B.D., Fournier K.F., Mansfield P.F., Ajani J.A., Badgwell B.D. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018; 117(8): 1721-8. doi:10.1002/jso.25081.; Sandø A.D., Fougner R., Grønbech J.E., Bringeland E.A. The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World J Surg Oncol. 2021; 19(1): 212. doi:10.1186/s12957-021-02313-3.; https://www.siboncoj.ru/jour/article/view/2588
-
12Academic Journal
Authors: V. Yu. Skoropad, D. D. Kudriavtsev, V. N. Shitareva, E. S. Zhavoronkovа, В. Ю. Скоропад, Д. Д. Кудрявцев, В. Н. Шитарева, Е. С. Жаворонкова
Source: Siberian journal of oncology; Том 21, № 6 (2022); 164-169 ; Сибирский онкологический журнал; Том 21, № 6 (2022); 164-169 ; 2312-3168 ; 1814-4861
Subject Terms: динамическое наблюдение, perioperative chemotherapy FLOT, surgical treatment, gastrectomy, tumor response, follow-up, периоперационная химиотерапия FLOT, хирургическое лечение, гастрэктомия, лечебный патоморфоз
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2388/1065; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi:10.3322/caac.21660.; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021. 252 с.; Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., Lindig U., Schmiegel W., Pohl M., Stoehlmacher J., Folprecht G., Probst S., Prasnikar N., Fischbach W., Mahlberg R., Trojan J., Koenigsmann M., Martens U.M., Thuss-Patience P., Egger M., Block A., Heinemann V., Illerhaus G., Moehler M., Schenk M., Kullmann F., Behringer D.M., Heike M., Pink D., Teschendorf C., Löhr C., Bernhard H., Schuch G., Rethwisch V., von Weikersthal L.F., Hartmann J.T., Kneba M., Daum S., Schulmann K., Weniger J., Belle S., Gaiser T., Oduncu F.S., Güntner M., Hozaeel W., Reichart A., Jäger E., Kraus T., Mönig S., Bechstein W.O., Schuler M., Schmalenberg H., Hofheinz R.D.; FLOT4-AIO Investigators. Perioperative chemotherapy with fuorouracil plus leucovorin, oxaliplatin, and docetaxel versus fuorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 1948–57. doi:10.1016/S0140-6736(18)32557-1.; Cho H., Nakamura J., Asaumi Y., Yabusaki H., Sakon M., Takasu N., Kobayashi T., Aoki T., Shiraishi O., Kishimoto H., Nunobe S., Yanagisawa S., Suda T., Ueshima S., Matono S., Maruyama H., Tatsumi M., Seya T., Tanizawa Y., Yoshikawa T. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature. Ann Surg Oncol. 2015; 22(3): 787–92. doi:10.1245/s10434-014-4084-9.; Hu Q., Wang J., Xu W-G., Shao P., Li G. Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy. Precision Medical Sciences. 2021; 10(2): 78–82. doi:10.1002/prm2.12038.; Трусилова Е.В., Бесова Н.С., Горбунова В.A., Глухов Е.В., Неред С.Н., Стилиди И.В., Меликов С.А., Перфильев И.Б., Бондаренко Ю.В. Полная патоморфологическая регрессия опухоли желудка после проведения неоадъювантной химиотерапии у больного местнораспространенным раком желудка. Клинический случай. Вестник РОНЦ им. Н. Н. Блохина РАМН. 2013; 24(1).; McLaren P.J., Barnes A.P., Terrell W.Z., Vaccaro G.M., Wiedrick J., Hunter J.G., Dolan J.P. Specifc gene expression profles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma. Am J Surg. 2017; 213(5): 915–20. doi:10.1016/j.amjsurg.2017.03.024.; Мозеров С.А., Скоропад В.Ю., Новиков Н.Ю., Михайлова Г.Ф., Силантьева Н.К., Агабабян Т.А., Бекетова О.Г., Комин Ю.А., Чаиркин И.Н., Пашкин С.Б., Мозерова Е.С. Гистологическая и молекулярногенетическая оценка ответа опухоли на химио-лучевую терапию при раке желудка. Современные проблемы науки и образования. 2017; (4): 76. doi:10.17513/spno.26684.; Sun J., Wang X., Zhang Z., Zeng Z., Ouyang S., Kang W. The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. Front Oncol. 2021; 11. doi:10.3389/fonc.2021.641304.; https://www.siboncoj.ru/jour/article/view/2388
-
13Academic Journal
Authors: Сенютович, P., Бабін, B., Унгурян, B.
Source: Clinical anatomy and operative surgery; Vol. 4 No. 2 (2005); 52-54
Клиническая анатомия и оперативная хирургия; Том 4 № 2 (2005); 52-54
Клінічна анатомія та оперативна хірургія; Том 4 № 2 (2005); 52-54Subject Terms: рак, пищевод, желудок, эзофаго гастрэктомия, cancer, esophagus, stomach, esophagogastrectomy, стравохід, шлунок, езофагогастректомія, 3. Good health
File Description: application/pdf
Access URL: http://kaos.bsmu.edu.ua/article/view/259609
-
14Academic Journal
Authors: R. V. Pavlov, K. O. Timofeeva, M. A. Chernykh, V. N. Danilin, Р. В. Павлов, К. О. Тимофеева, М. А. Черных, В. Н. Данилин
Source: Siberian journal of oncology; Том 21, № 2 (2022); 81-87 ; Сибирский онкологический журнал; Том 21, № 2 (2022); 81-87 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2022-21-2
Subject Terms: ускоренная реабилитация, gastrectomy, nutritional support, early oral nutrition, enteral nutrition, fast-track surgery, perioperative care, гастрэктомия, послеоперационная нутритивная поддержка, раннее пероральное питание, энтеральное питание
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2092/972; Machlowska J., Baj J., Sitarz M., Maciejewski R., Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020; 21(11): 4012. doi:10.3390/ijms21114012.; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi:10.3322/caac.21660.; Kim Y.W., Baik Y.H., Yun Y.H., Nam B.H., Kim D.H., Choi I.J., Bae J.M. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg. 2008; 248(5): 721–7. doi:10.1097/SLA.0b013e318185e62e.; Park J.M., Jin S.H., Lee S.R., Kim H., Jung I.H., Cho Y.K., Han S.U. Complications with laparoscopically assisted gastrectomy: multivariate analysis of 300 consecutive cases. Surg Endosc. 2008; 22(10): 2133–9. doi:10.1007/s00464-008-9962-4.; Kanda M., Mizuno A., Tanaka C., Kobayashi D., Fujiwara M., Iwata N., Hayashi M., Yamada S., Nakayama G., Fujii T., Sugimoto H., Koike M., Takami H., Niwa Y., Murotani K., Kodera Y. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (Baltimore). 2016; 95(24): 3781. doi:10.1097/MD.0000000000003781.; Пасечник И.Н., Губайдуллин Р.Р., Борисов А.Ю. Основы нутритивной поддержки больных в критических состояниях. М., 2012. 160 с.; Hur H., Kim S.G., Shim J.H., Song K.Y., Kim W., Park C.H., Jeon H.M. Effect of early oral feeding after gastric cancer surgery: a result of randomized clinical trial. Surgery. 2011; 149(4): 561–8. doi:10.1016/j.surg.2010.10.003.; Laffitte A.M., Polakowski C.B., Kato M. Early oral re-feeding on oncology patients submitted to gastrectomy for gastric cancer. Arq Bras Cir Dig. 2015; 28(3): 200–3. doi:10.1590/S0102-67202015000300014.; Sierzega M., Choruz R., Pietruszka S., Kulig P., Kolodziejczyk P., Kulig J. Feasibility and outcomes of early oral feeding after total gastrectomy for cancer. J Gastrointest Surg. 2015; 19(3): 473–9. doi:10.1007/s11605-014-2720-0.; Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., Fearon K., Hütterer E., Isenring E., Kaasa S., Krznaric Z., Laird B., Larsson M., Laviano A., Mühlebach S., Muscaritoli M., Oldervoll L., Ravasco P., Solheim T., Strasser F., de van der Schueren M., Preiser J.C. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017; 36(1): 11–48. doi:10.1016/j.clnu.2016.07.015.; Lassen K., Soop M., Nygren J., Cox P.B., Hendry P.O., Spies C., von Meyenfeldt M.F., Fearon K.C., Revhaug A., Norderval S., Ljungqvist O., Lobo D.N., Dejong C.H.; Enhanced Recovery After Surgery (ERAS) Group. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg. 2009; 144(10): 961–9. doi:10.1001/archsurg.2009.170.; Lassen K., Coolsen M.M., Slim K., Carli F., de Aguilar-Nascimento J.E., Schäfer M., Parks R.W., Fearon K.C., Lobo D.N., Demartines N., Braga M., Ljungqvist O., Dejong C.H.; ERAS® Society; European Society for Clinical Nutrition and Metabolism; International Association for Surgical Metabolism and Nutrition. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr. 2012; 31(6): 817–30. doi:10.1016/j.clnu.2012.08.011.; Mortensen K., Nilsson M., Slim K., Schäfer M., Mariette C., Braga M., Carli F., Demartines N., Griffin S.M., Lassen K.; Enhanced Recovery After Surgery (ERAS®) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014; 101(10): 1209–29. doi:10.1002/bjs.9582.; Jang A., Jeong O. Early Postoperative Oral Feeding After Total Gastrectomy in Gastric Carcinoma Patients: A Retrospective Before-After Study Using Propensity Score Matching. J Parenter Enteral Nutr. 2019; 43(5): 649–57. doi:10.1002/jpen.1438.; Ford S.J., Adams D., Dudnikov S., Peyser P., Rahamim J., Wheatley T.J., Berrisford R.G., Sanders G. The implementation and effectiveness of an enhanced recovery programme after oesophago-gastrectomy: a prospective cohort study. Int J Surg. 2014; 12(4): 320–4. doi:10.1016/j.ijsu.2014.01.015.; Lu Y.X., Wang Y.J., Xie T.Y., Li S., Wu D., Li X.G., Song Q.Y., Wang L.P., Guan D., Wang X.X. Effects of early oral feeding after radical total gastrectomy in gastric cancer patients. World J Gastroenterol. 2020; 26(36): 5508–19. doi:10.3748/wjg.v26.i36.5508.; Chen Z.X., Liu A.H., Cen Y. Fast-track program vs traditional care in surgery for gastric cancer. World J Gastroenterol. 2014; 20(2): 578–83. doi:10.3748/wjg.v20.i2.578.; Liu G., Jian F., Wang X., Chen L. Fast-track surgery protocol in elderly patients undergoing laparoscopic radical gastrectomy for gastric cancer: a randomized controlled trial. Onco Targets Ther. 2016; 9: 3345–51. doi:10.2147/OTT.S107443.; https://www.siboncoj.ru/jour/article/view/2092
-
15Academic Journal
Authors: N. V. Kovalenko, V. V. Zhavoronkova, M. P. Postolov, V. A. Suvorov, Н. В. Коваленко, В. В. Жаворонкова, М. П. Постолов, В. А. Суворов
Source: Siberian journal of oncology; Том 21, № 3 (2022); 126-134 ; Сибирский онкологический журнал; Том 21, № 3 (2022); 126-134 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2022-21-3
Subject Terms: профилактическая гастрэктомия, hereditary tumor, diffuse type, CDH1 mutation, prophylactic total gastrectomy, CDH1
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2170/995; Sahasrabudhe R., Lott P., Bohorquez M., Toal T., Estrada A.P., Suarez J.J., Brea-Fernández A., Cameselle-Teijeiro J., Pinto C., Ramos I., Mantilla A., Prieto R., Corvalan A., Norero E., Alvarez C., Tapia T., Carvallo P., Gonzalez L.M., Cock-Rada A., Solano A., Neffa F., Della Valle A., Yau C., Soares G., Borowsky A., Hu N., He L.J., Han X.Y.; Latin American Gastric Cancer Genetics Collaborative Group, Taylor P.R., Goldstein A.M., Torres J., Echeverry M., Ruiz-Ponte C., Teixeira M.R., Carvajal-Carmona L.G. Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. Gastroenterology. 2017; 152(5): 983–6. doi:10.1053/j. gastro.2016.12.010.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019; 236 с.; van der Post R.S., Gullo I., Oliveira C., Tang L.H., Grabsch H.I., O’Donovan M., Fitzgerald R.C., van Krieken H., Carneiro F. Histopathological, Molecular, and Genetic Profle of Hereditary Difuse Gastric Cancer: Current Knowledge and Challenges for the Future. Adv Exp Med Biol. 2016; 908: 371–91. doi:10.1007/978-3-319-41388-4_18.; Lyubchenko L.N., Filippova M.G., Anurova O.A., Nazliev P.B., Stilidi I.S. Hereditary difuse gastric cancer: genetic aspects and prophylactic total gastrectomy. Siberian Journal of Oncology. 2018; 17(4): 48–52. doi.10.21294/1814-4861-2018-17-4-48-52.; Белковец А.В., Курилович С.А., Решетников О.В. Наследственный рак желудка (научный обзор). Int J Appl Fundam Res. 2016; 1: 516–22; Штефанов И.И., Кулмамбетова Г.Н., Айткулова А.М., Жекеева Ж.Т., Бакиров Н.Д., Пироженко О.Л., Губская Е.Б., Котов И.В., Жакипова А.А., Мироедова Э.П., Макишева А.К. Значение экспрессии e-cadherin при наследственном диффузном раке желудка. Медицина (Алматы). 2019; 200(2): 8–12.; van der Post R.S., Vogelaar I.P., Carneiro F., Guilford P., Huntsman D., Hoogerbrugge N., Caldas C., Schreiber K.E., Hardwick R.H., Ausems M.G., Bardram L., Benusiglio P.R., Bisseling T.M., Blair V., Bleiker E., Boussioutas A., Cats A., Coit D., DeGregorio L., Figueiredo J., Ford J.M., Heijkoop E., Hermens R., Humar B., Kaurah P., Keller G., Lai J., Ligtenberg M.J., O’Donovan M., Oliveira C., Pinheiro H., Ragunath K., Rasenberg E., Richardson S., Roviello F., Schackert H., Seruca R., Taylor A., Ter Huurne A., Tischkowitz M., Joe S.T., van Dijck B., van Grieken N.C., van Hillegersberg R., van Sandick J.W., Vehof R., van Krieken J.H., Fitzgerald R.C. Hereditary difuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015; 52(6): 361–74. doi:10.1136/jmedgenet-2015-103094.; Blair V.R., McLeod M., Carneiro F., Coit D.G., D’Addario J.L., van Dieren J.M., Harris K.L., Hoogerbrugge N., Oliveira C., van der Post R.S., Arnold J., Benusiglio P.R., Bisseling T.M., Boussioutas A., Cats A., Charlton A., Schreiber K.E.C., Davis J.L., Pietro M.D., Fitzgerald R.C., Ford J.M., Gamet K., Gullo I., Hardwick R.H., Huntsman D.G., Kaurah P., Kupfer S.S., Latchford A., Mansfeld P.F., Nakajima T., Parry S., Rossaak J., Sugimura H., Svrcek M., Tischkowitz M., Ushijima T., Yamada H., Yang H.K., Claydon A., Figueiredo J., Paringatai K., Seruca R., BougenZhukov N., Brew T., Busija S., Carneiro P., DeGregorio L., Fisher H., Gardner E., Godwin T.D., Holm K.N., Humar B., Lintott C.J., Monroe E.C., Muller M.D., Norero E., Nouri Y., Paredes J., Sanches J.M., Schulpen E., Ribeiro A.S., Sporle A., Whitworth J., Zhang L., Reeve A.E., Guilford P. Hereditary difuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020; 21(8): 386–97. doi:10.1016/S1470-2045(20)30219-9.; Hakkaart C., Ellison-Loschmann L., Day R., Sporle A., Koea J., Harawira P., Cheng S., Gray M., Whaanga T., Pearce N., Guilford P. Germline CDH1 mutations are a signifcant contributor to the high frequency of early-onset difuse gastric cancer cases in New Zealand Māori. Fam Cancer. 2019; 18(1): 83–90. doi:10.1007/s10689-018-0080-8.; Seevaratnam R., Coburn N., Cardoso R., Dixon M., Bocicariu A., Helyer L. A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary difuse gastric cancer. Gastric Cancer. 2012; 15(1): 153–63. doi:10.1007/s10120-011-0116-3.; Guilford P., Humar B., Blair V. Hereditary difuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010; 13(1): 1–10. doi:10.1007/s10120-009-0531-x.; Цуканов А.С., Шелыгин Ю.А., Кашников В.Н., Фролов С.А., Любченко Л.Н., Шубин В.П., Карпухин А.В., Музаффарова Т.А., Поспехова Н.И. Молекулярно-генетическое исследование наследственной предрасположенности к диффузному раку желудка у российских пациентов. Вопросы онкологии. 2013; 59(5): 580–4.; Corso G., Marrelli D., Pascale V., Vindigni C., Roviello F. Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer. 2012; 12: 8. doi:10.1186/1471-2407-12-8.; Munitiz Ruiz V., Jimeno P., Ruiz de Angulo D., Ortiz Á., Martínez de Haro L.F., Marín M., Cascales P., Ruiz García G., Ortiz Ruiz E., Parrilla P. Is prophylactic gastrectomy indicated for healthy carriers of CDH1 gene mutations associated with hereditary difuse gastric cancer? Rev Esp Enferm Dig. 2019; 111(3): 189–92. doi:10.17235/reed.2018.5831/2018.; Selvanathan A., Nixon C.Y., Zhu Y., Scietti L., Forneris F., Uribe L.M.M., Lidral A.C., Jezewski P.A., Mulliken J.B., Murray J.C., Buckley M.F., Cox T.C., Roscioli T. CDH1 Mutation Distribution and Type Suggests Genetic Diferences between the Etiology of Orofacial Clefting and Gastric Cancer. Genes (Basel). 2020; 11(4): 391. doi:10.3390/ genes11040391.; Bougen-Zhukov N., Nouri Y., Godwin T., Taylor M., Hakkaart C., Single A., Brew T., Permina E., Chen A., Black M.A., Guilford P. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-CadherinDefcient Cells. Cancers (Basel). 2019; 11(9): 1359. doi:10.3390/cancers11091359.; Shenoy S. CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management. Cancer Manag Res. 2019; 11: 10477–86. doi:10.2147/CMAR.S208818.; Majewski I.J., Kluijt I., Cats A., Scerri T.S., de Jong D., Kluin R.J., Hansford S., Hogervorst F.B., Bosma A.J., Hofland I., Winter M., Huntsman D., Jonkers J., Bahlo M., Bernards R. An α-E-catenin (CTNNA1) mutation in hereditary difuse gastric cancer. J Pathol. 2013; 229(4): 621–9. doi:10.1002/path.4152.; Hansford S., Kaurah P., Li-Chang H., Woo M., Senz J., Pinheiro H., Schrader K.A., Schaeffer D.F., Shumansky K., Zogopoulos G., Santos T.A., Claro I., Carvalho J., Nielsen C., Padilla S., Lum A., Talhouk A., BakerLange K., Richardson S., Lewis I., Lindor N.M., Pennell E., MacMillan A., Fernandez B., Keller G., Lynch H., Shah S.P., Guilford P., Gallinger S., Corso G., Roviello F., Caldas C., Oliveira C., Pharoah P.D., Huntsman D.G. Hereditary Difuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015; 1(1): 23–32. doi:10.1001/jamaoncol.2014.168.; Benusiglio P.R., Colas C., Guillerm E., Canard A., Delhomelle H., Warcoin M., Bellanger J., Eyries M., Zizi M., Netter J., Soubrier F., Parc Y., Mourregot A., Maran Gonzalez A., Cusin V., Denis J.A., Coupier I., Svrcek M., Coulet F. Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. Gastric Cancer. 2019; 22(4): 899–903. doi:10.1007/s10120-018-00907-7.; Gaston D., Hansford S., Oliveira C., Nightingale M., Pinheiro H., Macgillivray C., Kaurah P., Rideout A.L., Steele P., Soares G., Huang W.Y., Whitehouse S., Blowers S., LeBlanc M.A., Jiang H., Greer W., Samuels M.E., Orr A., Fernandez C.V., Majewski J., Ludman M., Dyack S., Penney L.S., McMaster C.R., Huntsman D., Bedard K. Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet. 2014; 10(10). doi:10.1371/journal.pgen.1004669.; Lewis F.R., Mellinger J.D., Hayashi A., Lorelli D., Monaghan K.G., Carneiro F., Huntsman D.G., Jackson C.E., Caldas C. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001; 130(4): 612–7. doi:10.1067/msy.2001.117099.; Laszkowska M., Silver E.R., Schrope B., Kastrinos F., Wang T.C., Hur C. Optimal Timing of Total Gastrectomy to Prevent Difuse Gastric Cancer in Individuals With Pathogenic Variants in CDH1. Clin Gastroenterol Hepatol. 2020; 18(4): 822–9. doi:10.1016/j.cgh.2019.06.009.; Hebbard P.C., Macmillan A., Huntsman D., Kaurah P., Carneiro F., Wen X., Kwan A., Boone D., Bursey F., Green J., Fernandez B., Fontaine D., Wirtzfeld D.A. Prophylactic total gastrectomy (PTG) for hereditary difuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol. 2009; 16(7): 1890–5. doi:10.1245/s10434- 009-0471-z.; DiBrito S.R., Blair A.B., Prasath V., Habibi M., Harmon J.W., Duncan M.D. Total Gastrectomy for CDH-1 Mutation Carriers: An Institutional Experience. J Surg Res. 2020; 247: 438–44. doi:10.1016/j. jss.2019.09.062.; Wang G., Ceng G., Zhou B., Chen Y., Jin C., Feng X. Meta-analysis of two types of digestive tract reconstruction modes after total gastrectomy. Hepatogastroenterology. 2013; 60(127): 1817–21.; van der Kaaij R.T., van Kessel J.P., van Dieren J.M., Snaebjornsson P., Balagué O., van Coevorden F., van der Kolk L.E., Sikorska K., Cats A., van Sandick J.W. Outcomes after prophylactic gastrectomy for hereditary difuse gastric cancer. Br J Surg. 2018; 105(2): 176–82. doi:10.1002/bjs.10754.; Strong V.E., Gholami S., Shah M.A., Tang L.H., Janjigian Y.Y., Schattner M., Selby L.V., Yoon S.S., Salo-Mullen E., Stadler Z.K., Kelsen D., Brennan M.F., Coit D.G. Total Gastrectomy for Hereditary Difuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg. 2017; 266(6): 1006–12. doi:10.1097/SLA.0000000000002030.; Kumar S., Long J.M., Ginsberg G.G., Katona B.W. The role of endoscopy in the management of hereditary difuse gastric cancer syndrome. World J Gastroenterol. 2019; 25(23): 2878–86. doi:10.3748/wjg. v25.i23.2878.; Lim Y.C., di Pietro M., O’Donovan M., Richardson S., Debiram I., Dwerryhouse S., Hardwick R.H., Tischkowitz M., Caldas C., Ragunath K., Fitzgerald R.C. Prospective cohort study assessing outcomes of patients from families fulflling criteria for hereditary difuse gastric cancer undergoing endoscopic surveillance. Gastrointest Endosc. 2014; 80(1): 78–87. doi:10.1016/j.gie.2013.11.040.; Moslim M.A., Heald B., Tu C., Burke C.A., Walsh R.M. Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary difuse gastric cancer. Surgery. 2018; 164(4): 754–9. doi:10.1016/j.surg.2018.05.059.; https://www.siboncoj.ru/jour/article/view/2170
-
16Academic Journal
Authors: N. N. Semenov, K. D. Dalgatov, Н. Н. Семёнов, К. Д. Далгатов
Source: Malignant tumours; Том 12, № 1 (2022); 44-50 ; Злокачественные опухоли; Том 12, № 1 (2022); 44-50 ; 2587-6813 ; 2224-5057
Subject Terms: метастазы, gastric cancer, MUC16, chemotherapy, gastrectomy, metastases, рак желудка, химиотерапия, гастрэктомия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/938/672; Bast RC, Jr., Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68 (5): 1331‑7. [PubMed: 7028788]; Klug TL, Bast RC, Jr., Niloff JM, et al. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 1984;44 (3):1048—53. [PubMed: 6198078]; Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98 (S): 737—40. [PubMed: 11920644]; S. Das, S. Rachagani, M. P. Torres ‑ Gonzalez et al. Carboxyl‑terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget. 2015 Mar 20;6 (8):5772‑87. doi:10.18632/oncotarget.3308.; M. Boivin, D. Lane, A. Piché CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug‑induced apoptosis. Gynecol Oncol. 2009 Dec;115 (3):407‑13. doi:10.1016/j.ygyno.2009.08.007. Epub 2009 Sep 10.; C. Thériault, M. Pinard, M. Comamala et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis Gynecol Oncol. 2011 Jun 1;121 (3):434‑43. doi:10.1016/j.ygyno.2011.02.020. Epub 2011 Mar 21.; S. Senapati, P. Sharma, S. Bafna, et al. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer. Histol Histopathol. 2008; 23:1541‑52. [PubMed: 18830939]; 8. S. Bafna, S. Kaur, S. K. Batra. Membrane‑bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010; 29:2893‑904. [PubMed: 20348949]; Kabawat, S. E., Bast, R. C., Bahn, A. K. et al. (1983) Tissue distribution of acoelomic‑ epithelium‑related antigen recognized by the monoclonal antibody OC 125. Int. J. Gynecol. Pathol., 2, 275 ‑285.; Zeillemaker, A. M., Verbrugh, H. A., Hoynck van Papendrecht, A. A. G. M. et al. CA125 secretion by peritoneal mesothelial cells. J. Clin. Pathol 47, 263‑265.; Zeimet, A. G., Offner, F. A., Muller‑Holzner, E. et al. (1998) Peritoneum and tissues of the female reproductive tract as physiological sources of CA125. Tumor Biol., 19, 275‑282; Jonckheere, I. Van Seuningen The membrane‑bound mucins: how large O ‑ glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene‑based and immunotherapies. Crit Rev Oncog. 2008: 14:177—96. (PubMed: 19409062]; RC. Bast Jr, D. R. Spriggs. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 2011, 121:429‑430; Gubbels JA, Felder M, Horibata S, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 2010;9:11. [PubMed: 20089172]; Belisle JA, Horibata S, Jennifer GA, et al. Identification of Siglec‑9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 2010;9:118. [PubMed: 20497550]; M. M. Streppel, A. Vincent, R. Mukherjee, et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012 October; 43 (10): 1755‑1763. doi:10.1016/j.humpath.2012.01.005; Kim DH, Yun HY, Ryu DH et al. Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World J Gastroenterol. 2015 Jan 28;21 (4):1216‑21. doi:10.3748/wjg.v21.i4.1216.; Namikawa T, Kawanishi Y, Fujisawa K, et al. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer. Surg Today. 2018 Apr;48 (4):388 ‑394. doi:10.1007/s00595‑017‑1598‑3. Epub 2017 Oct 17.; A. Perrier, J. Gligorov, G. Lefèvre, The extracellular domain of Her2 in serum as a biomarker of breast cancer. Lab Invest. 2018 Jun;98 (6):696‑707. doi:10.1038/s41374‑018‑0033‑8. Epub 2018 Feb 28.; K. Moreno‑Aspitia, D. W. Hillman, S. H. Dyar et al. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‑positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 2013 Aug 1;119 (15):2675‑82. doi:10.1002/cncr.28130. Epub 2013 Jun 6.; K. Oyama, S. Fushida, T. Tsukada et al. Evaluation of serum HER2‑ECD levels in patients with gastric cancer J Gastroenterol. 2015 Jan;50 (1):41‑5. doi:10.1007/s00535‑014‑0941‑3. Epub 2014 Feb 21.; H.‑Z Shi, Y.‑N. Wang, X.‑H. Huang et al. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer. World J Gastroenterol. 2017 Mar 14;23 (10):1836‑1842. doi:10.3748/wjg.v23.i10.1836.; M. Saito, K. Yamashita, Y. Arimura et al. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK). Acta Oncol. 2016;55 (3):309‑17. doi:10.3109/0284186X.2015.1107189. Epub 2016 Jan 12.; J. Berek, P. Taylor, W. McGuire, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27 (3):418‑25. doi:10.1200/JCO.2008.17.8400. Epub 2008 Dec 15.; P. Sabbatini, P. Harter, G. Scambia, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO ‑‑the MIMOSA study. J Clin Oncol. 2013 Apr 20;31 (12):1554‑61. doi:10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.; https://www.malignanttumors.org/jour/article/view/938
-
17Academic Journal
Authors: A. L. Potapov, V. E. Khoronenko, E. V. Gameeva, Zh. V. Khailova, A. D. Dorozhkin, V. Yu. Scoropad, А. Л. Потапов, В. Э. Хороненко, Е. В. Гамеева, Ж. В. Хайлова, А. Д. Дорожкин, В. Ю. Скоропад
Source: Research and Practical Medicine Journal; Том 8, № 1 (2021); 53-61 ; Research'n Practical Medicine Journal; Том 8, № 1 (2021); 53-61 ; 2410-1893 ; 10.17709/2409-2231-2021-8-1
Subject Terms: дополнительное пероральное питание, malnutrition, surgical treatment, gastrectomy, subtotal gastrectomy, oral nutritional supplements, недостаточность питания, хирургическое лечение, гастрэктомия, субтотальная резекция желудка
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/673/405; Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, et al. Clinical Impact of Sarcopenia on Gastric Cancer. Anticancer Res. 2019 May;39(5):2241–2249. https://doi.org/10.21873/anticanres.13340; Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017 Jun;36(3):623–650. https://doi.org/10.1016/j.clnu.2017.02.013; Lee Y, Yu J, Doumouras AG, Li J, Hong D. Enhanced recovery after surgery (ERAS) versus standard recovery for elective gastric cancer surgery: A meta-analysis of randomized controlled trials. Surg Oncol. 2020 Mar;32:75–87. https://doi.org/10.1016/j.suronc.2019.11.004; Wang L-H, Zhu R-F, Gao C, Wang S-L, Shen L-Z. Application of enhanced recovery after gastric cancer surgery: An updated meta-analysis. World J Gastroenterol. 2018 Apr 14;24(14):1562– 1578. https://doi.org/10.3748/wjg.v24.i14.1562; Потапов А.Л., Хороненко В.Э., Гамеева Е.В., Хайлова Ж.В., Бояркина А.В., Иванов С.А. и др. Дополнительное пероральное питание: прикладная классификация смесей и ключевые правила применении я в онкологии. Вопросы питания. 2020;89(1):69–76. https://doi.org/10.24411/0042-8833-2020-10008; Лейдерман И.Н., Грицан А.И., Заболотских И.Б., Ломидзе С.В., Мазурок В.А., Нехаев И.В. и др. Периоперационная нутритивная поддержка. Клинические рекомендации. Вестник интенсивной терапии им. А.И.Салтанова. 2018;3:5–21. https://doi.org/10.21320/1818-474X-2018-3-5-21; Kong S-H, Lee H-J, Na J-R, Kim WG, Han D-S, Park S-H, et al. Effect of perioperative oral nutritional supplementation in malnourished patients who undergo gastrectomy: A prospective randomized trial. Surgery. 2018 Dec;164(6):1263–1270. https://doi.org/10.1016/j.surg.2018.05.017; Сергиенко А.Д., Хороненко В.Э., Гамеева Е.В., Рябов А.Б., Хомяков В.М. Влияние нутритивной терапии на показатели качества жизни больных раком желудка на этапе хирургического лечения. Исследования и практика в медицине. 2019;6(3):108–114. https://doi.org/10.17709/2409-2231-2019-6-3-10; Chen X, Yang K, Zhang X, Li K. Meta-analysis of preoperative oral nutritional supplements for patients with gastric cancer: East Asian experience. Eur J Clin Nutr. 2020 Jul;74(7):991–1000. https://doi.org/10.1038/s41430-019-0483-0; Oh SE, Choi M-G, Seo J-M, An JY, Lee JH, Sohn TS, et al. Prognostic significance of perioperative nutritional parameters in patients with gastric cancer. Clin Nutr. 2019 Apr;38(2):870–876. https://doi.org/10.1016/j.clnu.2018.02.015; Yang Y, Gao P, Song Y, Sun J, Chen X, Zhao J, et al. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: A meta-analysis. Eur J Surg Oncol. 2016 Aug;42(8):1176–1182. https://doi.org/10.1016/j.ejso.2016.05.029; Migita K, Matsumoto S, Wakatsuki K, Ito M, Kunishige T, Nakade H, et al. A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy. Surg Today. 2017 Aug;47(8):1018–1026. https://doi.org/10.1007/s00595-017-1469-y; Bozzetti F. Chemotherapy-Induced Sarcopenia. Curr Treat Options Oncol. 2020 Jan 30;21(1):7. https://doi.org/10.1007/s11864-019-0691-9; Liu X, Wang D, Zheng L, Mou T, Liu H, Li G. Is early oral feeding after gastric cancer surgery feasible? A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(11):e112062. https://doi.org/10.1371/journal.pone.0112062; Willcutts KF, Chung MC, Erenberg CL, Finn KL, Schirmer BD, Byham-Gray LD. Early Oral Feeding as Compared with Traditional Timing of Oral Feeding After Upper Gastrointestinal Surgery: A Systematic Review and Meta-analysis. Ann Surg. 2016 Jul;264(1):54–63. https://doi.org/10.1097/SLA.0000000000001644; Nakaseko Y, Ohdaira H, Yoshida M, Kitajima M, Suzuki Y. Clinical pathway after gastrectomy for gastric cancer: A case series of laparoscopic gastrectomy and early oral intake with "iEatTM." Ann Med Surg (Lond). 2018 Jul;31:20–24. https://doi.org/10.1016/j.amsu.2018.03.023; Shimizu N, Oki E, Tanizawa Y, Suzuki Y, Aikou S, Kunisaki C, et al. Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trial. Surg Today. 2018 Sep;48(9):865– 874. https://doi.org/10.1007/s00595-018-1665-4; Davis JL, Selby LV, Chou JF, Schattner M, Ilson DH, Capanu M, et al. Patterns and Predictors of Weight Loss After Gastrectomy for Cancer. Ann Surg Oncol. 2016 May;23(5):1639–1645. https://doi.org/10.1245/s10434-015-5065-3; Kobayashi D, Ishigure K, Mochizuki Y, Nakayama H, Sakai M, Ito S, et al. Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301). Gastric Cancer. 2017 Jul;20(4):718–727. https://doi.org/10.1007/s10120-016-0668-3; Hatao F, Chen K-Y, Wu J-M, Wang M-Y, Aikou S, Onoyama H, et al. Randomized controlled clinical trial assessing the effects of oral nutritional supplements in postoperative gastric cancer patients. Langenbecks Arch Surg. 2017 Mar;402(2):203–211. https://doi.org/10.1007/s00423-016-1527-8; Meng Q, Tan S, Jiang Y, Han J, Xi Q, Zhuang Q, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial. Clin Nutr. 2021 Jan;40(1):40–46. https://doi.org/10.1016/j.clnu.2020.04.043; Cheng Y, Zhang J, Zhang L, Wu J, Zhan Z. Enteral immunonutrition versus enteral nutrition for gastric cancer patients undergoing a total gastrectomy: a systematic review and meta-analysis. BMC Gastroenterol. 2018 Jan 16;18(1):11. https://doi.org/10.1186/s12876-018-0741-y; Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11–48. https://doi.org/10.1016/j.clnu.2016.07.015; Ida S, Hiki N, Cho H, Sakamaki K, Ito S, Fujitani K, et al. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. Br J Surg. 2017 Mar;104(4):377–383. https://doi.org/10.1002/bjs.10417; Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E, et al. Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020 Aug;38:28–42. https://doi.org/10.1016/j.clnesp.2020.05.007; Костюченко А.Л., Костин Э.Д., Курыгин А.А. Энтеральное искусственное питание в интенсивной медицине. СПб.: «Специальная литература», 1996, 330 с.; Lidoriki I, Schizas D, Mylonas KS, Frountzas M, Mastoraki A, Pikoulis E, et al. Oral Nutritional Supplementation Following Upper Gastrointestinal Cancer Surgery: A Prospective Analysis Exploring Potential Barriers to Compliance. J Am Coll Nutr. 2020 Oct;39(7):650–656. https://doi.org/10.1080/07315724.2020.1723453; https://www.rpmj.ru/rpmj/article/view/673
-
18Academic Journal
Authors: Теплицкий, C.
Source: Clinical anatomy and operative surgery; Vol. 8 No. 3 (2009); 63-67
Клиническая анатомия и оперативная хирургия; Том 8 № 3 (2009); 63-67
Клінічна анатомія та оперативна хірургія; Том 8 № 3 (2009); 63-67Subject Terms: 2. Zero hunger, obesity, sleeve gastrectomy, gastric by-pass according to Roux's method, index of body weight, ожиріння, рукавна гастректомія, шлункове шунтування за методом Ру, індекс маси тіла, ожирениеж рукавная гастрэктомия, желудочное шунтирование по Ру, индекс массы тела
File Description: application/pdf
Access URL: http://kaos.bsmu.edu.ua/article/view/230791
-
19Academic Journal
Authors: Ivanov Y.V., Danilina E.S., Istomin N.P., Velichko E.A., Mamoshin A.V., Agibalov D.Y.
Source: Almanac of Clinical Medicine; Vol 48, No 6 (2020); 437-444 ; Альманах клинической медицины; Vol 48, No 6 (2020); 437-444 ; 2587-9294 ; 2072-0505
Subject Terms: gastrectomy, esophageal-intestinal anastomosis, manual and stapler suture, anastomosis failure, гастрэктомия, пищеводно-кишечный анастомоз, ручной и степлерный шов, несостоятельность анастомоза
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/1395/1277; https://almclinmed.ru/jour/article/view/1395
-
20Academic Journal
Authors: Kirkilevsky, S. I., Zhulkevych, I. V., Mashukov, A. A., Maksimovsky, V. E., Rybin, A. I., Tkachenko, O. I., Yarema, R. R., Osadchy, D. N., Ohorchak, M. A., Pirogov, V. V., Linekevich, V. A.
Source: Bulletin of Scientific Research; No. 4 (2018); 13-25 ; Вестник научных исследований; № 4 (2018); 13-25 ; Вісник наукових досліджень; № 4 (2018); 13-25 ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2018.4
Subject Terms: intraperitoneal hyperthermic chemoperfusion, abdominal carcinomatosis, gastric cancer, cytoreductive surgery, peritoneal carcinomatosis index, gastrectomy, survival rate, systemic chemotherapy, внутрибрюшная гипертермическая химиоперфузия, канцероматоз брюшной полости, рак желудка, циторедуктивная хирургия, перитонеальный индекс канцероматоза, гастрэктомия, выживаемость, системная химиотерапия, внутрішньочеревна гіпертермічна хіміоперфузія, канцероматоз черевної порожнини, рак шлунка, циторедуктивна хірургія, перитонеальний індекс канцероматозу, гастректомія, виживання, системна хіміотерапія
File Description: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/visnyk-nauk-dos/article/view/9796/9458; https://repository.tdmu.edu.ua//handle/123456789/12762